Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for ...
Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...
Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval ...
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not applicable; NGS, next-generation sequencing; PCR, polymerase chain reaction. Fig 1. Kaplan-Meier estimates of (A) ...
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...
Scratch out your Tuesday and Wednesday nights, Champions League football is nearly upon us once more. Paris Saint-Germain are set to defend their European crown after winning last season’s competition ...
USA: A post-hoc analysis of phase III clinical trials suggests that tralokinumab demonstrates consistent efficacy and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results